Literature DB >> 24850369

Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia.

G Fervaha1, G Foussias, O Agid, G Remington.   

Abstract

OBJECTIVE: Functional impairment is characteristic of most individuals with schizophrenia; however, the key variables that undermine community functioning are not well understood. This study evaluated the association between selected clinical variables and one-year longitudinal functional outcomes in patients with schizophrenia.
METHOD: The sample included 754 patients with schizophrenia who completed both baseline and one-year follow-up visits in the CATIE study. Patients were evaluated with a comprehensive battery of assessments capturing symptom severity and cognitive performance among other variables. The primary outcome variable was functional status one-year postbaseline measured using the Heinrichs-Carpenter Quality of Life Scale.
RESULTS: Factor analysis of negative symptom items revealed two factors reflecting diminished expression and amotivation. Multivariate regression modeling revealed several significant independent predictors of longitudinal functioning scores. The strongest predictors were baseline amotivation and neurocognition. Both amotivation and neurocognition also had independent predictive value for each of the domains of functioning assessed (e.g., vocational).
CONCLUSION: Both motivational and neurocognitive deficits independently contribute to longitudinal functional outcomes assessed 1 year later among patients with schizophrenia. Both of these domains of psychopathology impede functional recovery; hence, it follows that treatments ameliorating each of these symptoms should promote community functioning among individuals with schizophrenia.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  amotivation; avolition-apathy; functional outcome; negative symptoms; neurocognition; schizophrenia

Mesh:

Year:  2014        PMID: 24850369     DOI: 10.1111/acps.12289

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  63 in total

Review 1.  [Standards for treatment in forensic committment according to § 63 and § 64 of the German criminal code : Interdisciplinary task force of the DGPPN].

Authors:  J L Müller; N Saimeh; P Briken; S Eucker; K Hoffmann; M Koller; T Wolf; M Dudeck; C Hartl; A-K Jakovljevic; V Klein; G Knecht; R Müller-Isberner; J Muysers; K Schiltz; D Seifert; A Simon; H Steinböck; W Stuckmann; W Weissbeck; C Wiesemann; R Zeidler
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

Review 2.  A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis.

Authors:  Gregory P Strauss; Andrea Pelletier-Baldelli; Katherine Frost Visser; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Res       Date:  2020-06-07       Impact factor: 4.939

3.  Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.

Authors:  Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-03-01       Impact factor: 4.785

4.  Clarifying the overlap between motivation and negative symptom measures in schizophrenia research: A meta-analysis.

Authors:  Lauren Luther; Melanie W Fischer; Ruth L Firmin; Michelle P Salyers
Journal:  Schizophr Res       Date:  2018-12-19       Impact factor: 4.939

Review 5.  Reconsidering the Latent Structure of Negative Symptoms in Schizophrenia: A Review of Evidence Supporting the 5 Consensus Domains.

Authors:  Gregory P Strauss; Anthony O Ahmed; Jared W Young; Brian Kirkpatrick
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

6.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

7.  Antipsychotics and amotivation.

Authors:  Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; George Foussias; Paul J Fletcher; Ofer Agid; Gary Remington
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

8.  Predictors of neuropsychological effort test performance in schizophrenia.

Authors:  Lindsay F Morra; James M Gold; Sara K Sullivan; Gregory P Strauss
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

Review 9.  A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors:  Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Clin Psychol Rev       Date:  2018-04-07

10.  Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia.

Authors:  Fernando Caravaggio; Gagan Fervaha; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Shinichiro Nakajima; Wanna Mar; Philip Gerretsen; Julia Kim; M Mallar Chakravarty; Benoit Mulsant; Bruce Pollock; David Mamo; Gary Remington; Ariel Graff-Guerrero
Journal:  Int J Geriatr Psychiatry       Date:  2017-11-07       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.